Metraipolis › archive › dc_1ca2ce019125
A first-in-human, open-label multicentre Phase 1 study of the orally administered E7386 in patients with selected advanced neoplasms — Europe PMC PMID:42243349
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42243349
- DOI
- 10.1038/s41416-[numero omesso]-w
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-08T00:57:44.124Z
- SHA-256 of the archived text
8848f087f1072ee2a28fb1182950e95e893a26cb1cb383aee78cc6346917a4b6- Stable URL of this page
https://metraipolis.com/documento/dc_1ca2ce019125
How to cite
A first-in-human, open-label multicentre Phase 1 study of the orally administered E7386 in patients with selected advanced neoplasms — Europe PMC PMID:42243349 — Europe PMC (en), https://europepmc.org/article/MED/42243349 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_1ca2ce019125 (Metraipolis archive dc_1ca2ce019125, sha256 8848f087f1072ee2a28fb1182950e95e893a26cb1cb383aee78cc6346917a4b6)
BibTeX
@misc{dc1ca2ce019125,
title = {A first-in-human, open-label multicentre Phase 1 study of the orally administered E7386 in patients with selected advanced neoplasms — Europe PMC PMID:42243349},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42243349},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_1ca2ce019125; sha256 8848f087f1072ee2a28fb1182950e95e893a26cb1cb383aee78cc6346917a4b6},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42243349. Agents can read the archived copy with the MCP tool read_document.